Pulmonary Artery Doppler and Neonatal Outcome in Placenta Accreta Spectrum Patients

Sponsor
Cairo University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04911322
Collaborator
(none)
60
1
12.6
4.8

Study Details

Study Description

Brief Summary

To correlate ultrasonographic markers of fetal lung maturity including Pulmonary artery Doppler indices in the late preterm and early term in placenta accreta spectrum patients with neonatal outcome.

Condition or Disease Intervention/Treatment Phase
  • Device: ultrasonography

Detailed Description

The increasing rates of cesarean section has led to several fold increase in the incidence of placenta accreta spectrum in the last three or four decades.

Placenta accreta spectrum (PAS) disorders is the term used to describe a variety of pregnancy complications resulting from abnormal placental implantation that is accompanied by deficiency of the uterine wall.

Placenta accreta spectrum includes placenta accreta, placenta increta, placenta percreta.

Placenta accreta spectrum is one of the devastating obstetric complications owing to massive hemorrhage encountered during manual removal of the placenta to preserve the uterus or even the need for peripartum hysterectomy, need for massive blood transfusion, maternal intensive care admission and maternal mortality.

Complications related to blood loss are lower in elective compared to emergency deliveries. This has led to the scheduling of surgical interventions with planned late preterm (35-36 weeks) or early term (37 weeks) delivery as a mechanism to avoid the need for emergency surgery. According to the RCOG guidelines, planned delivery at 35 0/7- 36 0/7 weeks of gestation provides the best chance between fetal maturity and the risk of unscheduled delivery while ACOG recommends 34 0/7- 35 6/7.

Early attempts have been made to predict fetal maturity on the basis antenatal sonographic parameters including lung characteristics, bowel pattern, placental grading (which cannot be relied upon in patients with placenta accreta spectrum), and the presence or absence of intraamniotic particles (vernix caseosa).

Additionally, the epiphyseal ossification centers appear and enlarge at variable rates but in a predictable sequence: the distal femoral epiphysis (DFE) appears prior to the proximal tibial epiphysis (PTE), which precedes the appearance of the proximal humeral epiphysis (PHE). The PTE grows more rapidly than does the DFE so that, as gestation progresses, the size of the PTE approaches that of the DFE.

More recently, fetal pulmonary artery Doppler has been used to predict neonatal RDS. It was found that an elevated acceleration-to-ejection time ratio was significantly associated with neonatal RDS. However such indices cannot be generalized in all cases, especially those with placenta accreta spectrum who have excessive placental shunting affecting fetoplacental circulation resistance.

To the best of our knowledge, no available studies have correlated signs of maturity of the fetus detected by ultrasound with neonatal outcomes in the late preterm and early term in such patients. Presence of such signs of maturity can aid the obstetrician to choose the most appropriate timing for termination especially in low income countries who have limited access to NICUs.

Being cost effective and non invasive, ultrasonography is used as a routine obstetric scanning tool. This study will help determine the utility of ultrasound in assessing the fetal lung maturity in such patients.

Study Design

Study Type:
Observational
Anticipated Enrollment :
60 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
Correlation Between Pulmonary Artery Doppler And Other Ultrasonographic Markers With Neonatal Outcome In Placenta Accreta Spectrum Patients
Actual Study Start Date :
Aug 15, 2021
Anticipated Primary Completion Date :
Aug 1, 2022
Anticipated Study Completion Date :
Sep 1, 2022

Outcome Measures

Primary Outcome Measures

  1. Acceleration time to ejection time (At/Et) ratio of fetal pulmonary artery Doppler in neonates with good and poor outcome. [Baseline]

    (At/Et) ratio will be measured in the fetal main pulmonary artery Doppler and will be correlated with the neonatal outcome

Secondary Outcome Measures

  1. The pulsatility index (PI) of the fetal pulmonary artery Doppler in neonates with good and poor outcome. [Baseline]

    The PI will be measured in the fetal main pulmonary artery and will be correlated with the neonatal outcome

  2. The resistance index (RI) of the fetal pulmonary artery Doppler in neonates with good and poor outcome [Baseline]

    RI will be measured in the fetal main pulmonary artery and will be correlated with the neonatal outcome

  3. The systolic to diastolic ratio (S/D) of the fetal pulmonary artery Doppler in neonates with good and poor outcome [Baseline]

    S/D will be measured in the fetal main pulmonary artery and will be correlated with the neonatal outcome

  4. The peak systolic velocity (PSV) of the fetal pulmonary artery Doppler in neonates with good and poor outcome [Baseline]

    PSV will be measured in the fetal main pulmonary artery and will be correlated with the neonatal outcome

  5. Optimal timing of delivery in PAS for best neonatal outcome [baseline]

    according to the neonatal outcome, the best timing for delivery will be determined

  6. Optimal timing of delivery in PAS for best maternal outcome [baseline]

    according to the maternal mortality and morbidity rate, the best timing for delivery will be obtained

  7. percent of women who will undergo cesarean hysterectomy versus conservative management [baseline]

    surgical management options; cesarean hysterectomy and conservative management will be recorded

  8. The need for blood transfusion [baseline]

    The need for replacement by blood or blood products will be recorded

  9. Maternal morbidity in the form of organ injury will be recorded [baseline]

    Organ injury will be recorded

  10. The need for peripartum hysterectomy will be recorded [Baseline]

    The need for peripartum hysterectomy either in cases of abnormally invasive placenta or in cases of abnormally adherent placenta in which the placenta separated but with uncontrollable bleeding

  11. Maternal mortality rate [Baseline]

    Rate of maternal mortality will be recorded

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 42 Years
Sexes Eligible for Study:
Female
Inclusion Criteria:
  • Age: 18-42 years old

  • Patients who will be diagnosed with placenta accreta spectrum preoperatively according to (ACOG 2018), (Jauniaux et al., 2018 a), (Jauniaux et al., 2018 b)

  • Those who will undergo elective or emergency cesarean.

  • With gestational age: 34 0/7 - 38 6/7 weeks

  • Under the effect of general anesthesia

Exclusion Criteria:
  • Multifetal pregnancy

  • Intrauterine fetal death

  • Intrauterine growth restriction (IUGR) which is defined as a rate of fetal growth that is less than normal for the growth potential of that specific infant

  • Diabetes with pregnancy either gestational or overt which is defined as any degree of glucose intolerance with an onset or first recognition during pregnancy

  • Pregnancy induced hypertension defined as either systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg. It is classified as one of four conditions: preexisting hypertension, gestational hypertension, preeclampsia, preexisting hypertension with superimposed preeclampsia

  • Premature rupture of membranes

  • BMI above 40 due to technical difficulties to obtain accurate measures

  • Narcotic usage during anesthesia before fetal delivery

  • Major congenital fetal anomalies whether diagnosed before or after delivery

  • Maternal fever more than 37.4 degree

  • Emergent cases presenting with fetal distress (bradycardia will be defined as fetal heart rate < 110 beat per minute)

  • Patients who have not completed the course of antenatal corticosteroids according to (RCOG 2010).

  • Intraoperative spontaneous separation of the placenta

Contacts and Locations

Locations

Site City State Country Postal Code
1 Kasralainy Cairo University Giza Egypt

Sponsors and Collaborators

  • Cairo University

Investigators

  • Study Director: Ahmed H El Sawaf, MD, Cairo University
  • Study Chair: Tarek M El Husseiny, MD, Cairo University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Noran Amin, Nominated demonstrator of Obstetrics and Gynecology, Cairo University, Cairo University
ClinicalTrials.gov Identifier:
NCT04911322
Other Study ID Numbers:
  • PAS disorders
First Posted:
Jun 3, 2021
Last Update Posted:
Sep 30, 2021
Last Verified:
Jun 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 30, 2021